InMode Posts $92.1M Q3 2026 Revenue, Holds Full-Year Outlook
InMode Ltd. reported third-quarter 2026 GAAP revenues of $92.1 million and reaffirmed its full-year 2026 financial guidance.
Medical technology company InMode Ltd. (Nasdaq: INMD) reported consolidated GAAP revenues of $92.1 million for the third quarter of 2026, the Israel-based firm announced Wednesday, as the maker of minimally invasive surgical devices maintained its annual financial outlook.
The Yokneam-headquartered company, which markets its platforms to plastic surgeons, dermatologists, and other specialists globally, reaffirmed its full-year 2026 financial guidance alongside the quarterly results, signaling management confidence in demand trends across its core product lines.
Read more Inverse Anthropic ETFs Give Traders Bearish Options on ANT Stock →
InMode has positioned itself as a provider of energy-based technologies used in body contouring, women's health, and other elective-procedure markets — segments that can be sensitive to consumer spending conditions and physician capital-equipment budgets. Reaffirming annual targets in that environment carries notable strategic weight.
The quarterly disclosure follows a period of heightened investor scrutiny of medical aesthetics companies, as the broader sector navigates shifting procedure volumes and competitive pressures from newer modalities. InMode's ability to hold its guidance intact may offer some reassurance to shareholders who have watched the stock face volatility in recent quarters.
Full details on operating income, net income, earnings per share, and updated annual guidance ranges were included in the company's formal earnings release. Continue reading at Earnings.